VOZMOZhNOSTI PRIMENENIYa SPIRAMITsINA V LEChENII RESPIRATORNYKh INFEKTsIY V PEDIATRIChESKOY PRAKTIKE


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

The article considers the characteristics of one of the first macrolide antibiotics - spiramycin. Spiramycin occupies a worthy place among the other macrolide antibiotics in the treatment of respiratory tract infections due to microbiological activity, pharmacokinetic parameters, and unique features of in vivo, data on clinical efficacy and safety, and population aspects of use of this drug.

Texto integral

Acesso é fechado

Bibliografia

  1. Gonzales R., Malone D.C., Maselli J.H., et al. Excessive antibiotic use for acute respiratory tract infecrions in the United States. Clin Infect Dis 2001; 33: 757-62.
  2. Ciesla G., Leader S., Stoddard J. Antibiotic prescribing rates in the US ambulatory care setting for patients diagnosed with influenza, 19972001. Respir Med 2004; 98(11): 1093-101.
  3. Carbon C. Pocket Pharma: Telithromycin and community-acquired respiratory tract infections. London, Current Medical Group Ltd 2005.
  4. Lui L., Roets E., Busson R., et al. Two novel spiramycins obtained from commercial samples; isolation and elucidation of structure. J Antibiot 1996; 49: 398-401.
  5. Di Giambattista M., Nyssen E., Engelborghs Y., et al. Kinetics of binding of macrolides, lincos-amides and synergimycins to ribosomes. J Biol Med 1987; 262: 8591-97.
  6. Bryskier A., Butzler J.-P. Macrolides. In: Antibiotic and Chemotherapy. Finch R.G., et al. Churchill Livingstone 2003: 310-25.
  7. Страчунский Л.С., Веселов А.В. Спирамицин: место в современной терапии (классика и современность) // Клиническая микробиология и антимикробная химиотерапия 2005. № 7. С. 286-97.
  8. Granizo J.J., Aguilar L., Casal J., et al. Streptococcus pneumoniae resistance to erythromycin and penicillin in relation to macrolide and fi-lactam consumption in Spain. J Antimicrob Chemother 2000; 46: 767-73.
  9. Козлов С.Н., Страчунский Л.С. Современная антимикробная химиотерапия. М., 2009. 448 с.
  10. Bergogne-Berezin E. Predicting antibiotic efficacy in respiratory tract infections. In: The 7th International Congress for Infectious Diseases. Hong Kong, 1996; abstr. 6003.
  11. Webster C., Ghazanfar K., Slack R. Sub-ingibitory and post-antibiotic effecrs of spiramycin and erythromycin on Staphylococcus aureus. J Antimicrob Chemother 1988; 22: 33-9.
  12. Wong S.-Y., Remington J.S. Toxoplasmosis in pregnancy. Clin Infect Dis 1994; 18: 853-62.
  13. Kamme C., Kahlmeter G., Melandae A. Evaluation of spiramycin as a therapeutic agent for elimination of nasapharyngeal pathogens. Scand J Infect Dis 1978; 10: 135-42.
  14. Яковлев С.В. Спирамицин (Ровамицин): вторая молодость макролидного антибиотика // Трудный пациент 2006. № 1(4). С. 3-6.
  15. Андреева И.В., Стецюк О.У. Инфекции дыхательных путей: новый взгляд на старые проблемы // Клин микробиол. антимикроб. химиотер. 2009. № 11 (2). С. 143-51.
  16. Bryskier A., Butzler J.-P. Macrolides. In: Antibiotic and Chemotherapy. Finch R.G., et al. Churchill Livingstone 2003: 310-25.
  17. Применение антибиотиков у детей в амбулаторной практике. Методические рекомендации / Под ред. А.А. Баранова и Л.С. Страчунского // Клин. микробиол. антимикроб. химиотер. 2007. № 9(3). С. 200-01.
  18. Esposito S., Bosis S., Faellis N., et al. Role of atypical bacteria and azithromycin therapy for children with recurrent respiratory tract infections. Pediatr Infect Dis J 2005; 24(5): 438-44.
  19. Bisno A.L., Pharyngitis. In: Mandell G.L., Bennett J.E., Dolin R., editors. Mandell, Douglas,and Bennett's principles and practice of infections diseases. 6th ed. Philadelphia, Churhill Livingstone 2005: 752-58.
  20. Linder J.A., Bates D.W., Lee G.M., et al. Antibiotic treatment of children with sore throat. JAMA 2005; 294(18): 2315-22.
  21. Esposito S. Aetiology of acute pharyngitis: the role of atypical bacteria. J Med Microbial 2004; 53: 645-51.
  22. Blasi F. Atypical pathogens and respiratory tract infections. Eur Respir J 2004; 24: 171-81.
  23. Gonzales R., Sande M.A. Uncomplicated acute bronchitis. Ann Intern Med 2001; 135(9): 839-40.
  24. Principi N., Esposito S., Cavagna R., et al. Recurrent respiratory tract infections in pediatric age: a population-based survey of the therapeutic role of macrolides. J Chemother 2003; 15(1): 53-9.
  25. Stelmach I., Podsiadlowicz-Borzeska M., Juralowicz D., et al. Analysis of possible causes of recurrent respiratory tract infections in children from Lodz, Poland. Pneumonol Alergol Pol 2003; 71(5-6): 237-44.
  26. Mayaud C. Epidemiology of acute lower respiratory tract infections in adults. Role of Chlamydia pneumoniae and Mycoplasma pneumoniae. Presse Med 1997; 26(26): 1248-53.
  27. Wangroongsarb P., Geenkajorn K., Pektanchanapong W., et al. Chlamydophila pneumoniae infection among young children with respiratory diseases in Thailand. Jpn J Infect Dis 2003; 56(4): 146-50.
  28. Ikezawa S. Prevalence of Chlamydia pneumoniae in acute respiratory tract infection and detection of anti-Chalamydia pneumoniae-specific IgE in Japanese children with reactive airway disease. Kurume Med 2001; 48(2): 165-70.
  29. Macfarlane J., Holmes W., Gard P., et al. Prospective study of the incidence, aetiology and outcome of adult lower respiratory tract illness in the community. Thorax 2001; 56(2): 109-14.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies